KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Net Income (2018 - 2025)

Historic Net Income for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Q3 2025 value amounting to $31.6 million.

  • Aurinia Pharmaceuticals' Net Income rose 12052.84% to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.9 million, marking a year-over-year increase of 44339.07%. This contributed to the annual value of $5.7 million for FY2024, which is 10736.27% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Net Income stood at $31.6 million, which was up 12052.84% from $21.5 million recorded in Q2 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' Net Income peaked at $31.6 million during Q3 2025, and registered a low of -$50.4 million during Q1 2021.
  • Over the past 5 years, Aurinia Pharmaceuticals' median Net Income value was -$13.4 million (recorded in 2023), while the average stood at -$15.0 million.
  • Its Net Income has fluctuated over the past 5 years, first plummeted by 9427.35% in 2021, then skyrocketed by 307300.88% in 2025.
  • Aurinia Pharmaceuticals' Net Income (Quarter) stood at -$33.3 million in 2021, then grew by 21.84% to -$26.0 million in 2022, then decreased by 3.34% to -$26.9 million in 2023, then surged by 105.47% to $1.5 million in 2024, then soared by 2041.96% to $31.6 million in 2025.
  • Its Net Income stands at $31.6 million for Q3 2025, versus $21.5 million for Q2 2025 and $23.3 million for Q1 2025.